LoadingLoadingLoadingNet selling: insiders sold $824K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full results8 funds hold a position and insiders have been net selling.
Buys/Adds (2)
Citadel
$174.7M
added
Point72
$75.7M
bought
Sells/Trims (1)
Balyasny
$38.4M
sold
Top-trader positions in ZBH could not be loaded.
Hyperliquid positioning - not every stock is covered
Last report
Aug 5, 2026
Period ending
Jun 30, 2026
Earnings per share
$2.01 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 23, 2026
EPS expected
$1.86 to $1.91
Revenue expected
24 analysts
Last 30 days
Analysts raising estimates
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 5, 2026 | $2.07 / $2.01Yahoo Finance | +2.99% beat | $2.18B No estimate | Unavailable |
| Mar 31, 2026 | Apr 28, 2026 | $2.09 / $1.86Yahoo Finance | +12.21% beat | $2.09B No estimate | Unavailable |
| Dec 31, 2025 | Feb 10, 2026 | $2.42 / $2.40Yahoo Finance | +0.93% in line | $2.24B No estimate | Unavailable |
| Sep 30, 2025 | Nov 5, 2025 | $1.90 / $1.87Yahoo Finance | +1.83% beat | $2.00B No estimate | Unavailable |
| Jun 30, 2025 | Aug 7, 2025 | $2.07 / $1.98Alpha Vantage | +4.55% beat | $2.08B No estimate | Unavailable |
| Mar 31, 2025 | May 5, 2025 | $1.81 / $1.77Alpha Vantage | +2.26% beat | $1.91B No estimate | Unavailable |
| Dec 31, 2024 | Feb 6, 2025 | $2.31 / $2.29Alpha Vantage | +0.87% in line | $2.02B No estimate | Unavailable |
| Sep 30, 2024 | Oct 30, 2024 | $1.74 / $1.74Alpha Vantage | +0.00% in line | $1.82B No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $2.00B | $2.24B | $2.09B | $2.18B |
| Cost of what it sold | $559.3M | $792.4M | $576.2M | $635.5M |
| Gross profit | $1.44B | $1.45B | $1.51B | $1.54B |
| What it spent | ||||
| Research and development | $115.9M | $118.8M | $103.4M | $104.8M |
| Sales and admin | $811.4M | $855.7M | $849.9M | $899.3M |
| Other operating costs | $163.5M | $189.1M | $184.0M | $211.3M |
| Total operating expenses | $1.09B | $1.16B | $1.14B | $1.22B |
| What was left | ||||
| Operating profit | $351.3M | $287.8M | $373.2M | $326.1M |
| Interest on debt | $75.4M | $71.9M | $68.8M | $72.9M |
| Profit before tax | $279.2M | $98.0M | $301.3M | $255.1M |
| Tax | $48.0M | -$39.9M | $63.0M | $55.5M |
| Net profit | $230.9M | $139.5M | $238.1M | $198.3M |
| EBITDA | $638.2M | $453.9M | $646.2M | $598.8M |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Zimmer Biomet Holdings, Inc. Estimates – SWB:ZIM
NeutralOct 23ResMed Inc. (RMD) Stock forecasts
NeutralOct 23Zimmer Biomet Holdings, Inc. (ZBH) Stock forecasts
BullishOct 22Zimmer Biomet Holdings, Inc. (ZBH) Stock forecasts
BullishOct 22Generate Biomedicines to present at two major h...
Leans bullishOct 22Stryker stock: BTIG cuts target from USD 358.00 to USD 316.00
Leans bearishOct 21Zimmer Biomet Holdings Inc. stock underperforms Wednesday when compared to competitors
NeutralOct 21Satellos Bioscience to present at healthcare investor conferences in November
Leans bearishOct 2131 macro signals shaping ZBH right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results